Reuters logo
BRIEF-Celsion says data monitoring committee recommends optima study continuation
November 30, 2016 / 1:30 PM / 10 months ago

BRIEF-Celsion says data monitoring committee recommends optima study continuation

Nov 30 (Reuters) - Celsion Corp :

* Press release - Celsion announces data monitoring committee unanimously recommends continuation of phase III optima study of Thermodox for primary liver cancer

* Celsion Corp says expects to complete patient enrollment in this 550 patient trial by early 2018 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below